PLA2G6 mutations in PARK14-linked young-onset parkinsonism and sporadic Parkinson's disease

Chin Song Lu, Szu Chia Lai, Ruey Meei Wu, Yi Hsin Weng, Chia Ling Huang, Rou Shayn Chen, Hsiu Chen Chang, Yah Huei Wu-Chou, Tu Hsueh Yeh

研究成果: 雜誌貢獻文章

40 引文 (Scopus)

摘要

Mutations of PLA2G6 gene have been lately proposed to be the causative gene for PARK14 in patients with autosomal recessive young-onset parkinsonism (YOPD). The role of PLA2G6 mutations as a risk factor for Parkinson's disease is not clear. To study the PLA2G6 mutations in PARK14-linked patients and its association with the onset of sporadic Parkinson's disease (sPD), sequencing and gene dosage analyses were carried out in 25 patients (onset age ≦30 years) then the identified variants were assessed in 956 sporadic PD (sPD) patients and 802 age-matched healthy controls. Four genetic variants were identified; one patient had homozygous c.991G>T (p.Asp331Tyr) mutation, two had compound heterozygous c.991G>T/c.1077G>A (p.Met358IlefsX) mutation, one had single c.1976A>G (p.Asn659Ser) mutation, and one patient had an exon 1 hetero-deletion. The c.1077G>A mutation resulted in a 4-bp deletion in leukocyte mRNA by activating a cryptic splice site in exon 7. Only p.Asp331Tyr was identified in four sPD patients and four controls. The onset age for PLA2G6 mutation carriers was younger than that for sPD (29.86±8.59 vs. 56.84±11.33 years, P=0.0002). The analysis of previously reported PARK14 patients revealed that those who carried a truncated mutation tended to have a complicated phenotype and atrophies of cortex and cerebellum. In conclusion, PLA2G6 mutation was the second common genetic cause after PRKN mutation in our YOPD patients and might be a risk factor for early-onset PD in Han Chinese. Additionally, mutation data should be interpreted carefully because even a synonymous mutation could cause abnormal mRNA splicing.
原文英語
頁(從 - 到)183-191
頁數9
期刊American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics
159 B
發行號2
DOIs
出版狀態已發佈 - 三月 2012
對外發佈Yes

指紋

Parkinsonian Disorders
Parkinson Disease
Mutation
Age of Onset
Exons
Messenger RNA
RNA Splice Sites
Gene Dosage
Cerebellum
Genes
Atrophy
Leukocytes
Phenotype

ASJC Scopus subject areas

  • Genetics(clinical)
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience

引用此文

PLA2G6 mutations in PARK14-linked young-onset parkinsonism and sporadic Parkinson's disease. / Lu, Chin Song; Lai, Szu Chia; Wu, Ruey Meei; Weng, Yi Hsin; Huang, Chia Ling; Chen, Rou Shayn; Chang, Hsiu Chen; Wu-Chou, Yah Huei; Yeh, Tu Hsueh.

於: American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics, 卷 159 B, 編號 2, 03.2012, p. 183-191.

研究成果: 雜誌貢獻文章

Lu, Chin Song ; Lai, Szu Chia ; Wu, Ruey Meei ; Weng, Yi Hsin ; Huang, Chia Ling ; Chen, Rou Shayn ; Chang, Hsiu Chen ; Wu-Chou, Yah Huei ; Yeh, Tu Hsueh. / PLA2G6 mutations in PARK14-linked young-onset parkinsonism and sporadic Parkinson's disease. 於: American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics. 2012 ; 卷 159 B, 編號 2. 頁 183-191.
@article{c30d160ffc5a4389b821b365b48843ad,
title = "PLA2G6 mutations in PARK14-linked young-onset parkinsonism and sporadic Parkinson's disease",
abstract = "Mutations of PLA2G6 gene have been lately proposed to be the causative gene for PARK14 in patients with autosomal recessive young-onset parkinsonism (YOPD). The role of PLA2G6 mutations as a risk factor for Parkinson's disease is not clear. To study the PLA2G6 mutations in PARK14-linked patients and its association with the onset of sporadic Parkinson's disease (sPD), sequencing and gene dosage analyses were carried out in 25 patients (onset age ≦30 years) then the identified variants were assessed in 956 sporadic PD (sPD) patients and 802 age-matched healthy controls. Four genetic variants were identified; one patient had homozygous c.991G>T (p.Asp331Tyr) mutation, two had compound heterozygous c.991G>T/c.1077G>A (p.Met358IlefsX) mutation, one had single c.1976A>G (p.Asn659Ser) mutation, and one patient had an exon 1 hetero-deletion. The c.1077G>A mutation resulted in a 4-bp deletion in leukocyte mRNA by activating a cryptic splice site in exon 7. Only p.Asp331Tyr was identified in four sPD patients and four controls. The onset age for PLA2G6 mutation carriers was younger than that for sPD (29.86±8.59 vs. 56.84±11.33 years, P=0.0002). The analysis of previously reported PARK14 patients revealed that those who carried a truncated mutation tended to have a complicated phenotype and atrophies of cortex and cerebellum. In conclusion, PLA2G6 mutation was the second common genetic cause after PRKN mutation in our YOPD patients and might be a risk factor for early-onset PD in Han Chinese. Additionally, mutation data should be interpreted carefully because even a synonymous mutation could cause abnormal mRNA splicing.",
keywords = "Multiple-ligation probe amplification (MLPA), PARK14, Parkinson's disease, PLA2G6, Splice site",
author = "Lu, {Chin Song} and Lai, {Szu Chia} and Wu, {Ruey Meei} and Weng, {Yi Hsin} and Huang, {Chia Ling} and Chen, {Rou Shayn} and Chang, {Hsiu Chen} and Wu-Chou, {Yah Huei} and Yeh, {Tu Hsueh}",
year = "2012",
month = "3",
doi = "10.1002/ajmg.b.32012",
language = "English",
volume = "159 B",
pages = "183--191",
journal = "American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics",
issn = "1552-4841",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - PLA2G6 mutations in PARK14-linked young-onset parkinsonism and sporadic Parkinson's disease

AU - Lu, Chin Song

AU - Lai, Szu Chia

AU - Wu, Ruey Meei

AU - Weng, Yi Hsin

AU - Huang, Chia Ling

AU - Chen, Rou Shayn

AU - Chang, Hsiu Chen

AU - Wu-Chou, Yah Huei

AU - Yeh, Tu Hsueh

PY - 2012/3

Y1 - 2012/3

N2 - Mutations of PLA2G6 gene have been lately proposed to be the causative gene for PARK14 in patients with autosomal recessive young-onset parkinsonism (YOPD). The role of PLA2G6 mutations as a risk factor for Parkinson's disease is not clear. To study the PLA2G6 mutations in PARK14-linked patients and its association with the onset of sporadic Parkinson's disease (sPD), sequencing and gene dosage analyses were carried out in 25 patients (onset age ≦30 years) then the identified variants were assessed in 956 sporadic PD (sPD) patients and 802 age-matched healthy controls. Four genetic variants were identified; one patient had homozygous c.991G>T (p.Asp331Tyr) mutation, two had compound heterozygous c.991G>T/c.1077G>A (p.Met358IlefsX) mutation, one had single c.1976A>G (p.Asn659Ser) mutation, and one patient had an exon 1 hetero-deletion. The c.1077G>A mutation resulted in a 4-bp deletion in leukocyte mRNA by activating a cryptic splice site in exon 7. Only p.Asp331Tyr was identified in four sPD patients and four controls. The onset age for PLA2G6 mutation carriers was younger than that for sPD (29.86±8.59 vs. 56.84±11.33 years, P=0.0002). The analysis of previously reported PARK14 patients revealed that those who carried a truncated mutation tended to have a complicated phenotype and atrophies of cortex and cerebellum. In conclusion, PLA2G6 mutation was the second common genetic cause after PRKN mutation in our YOPD patients and might be a risk factor for early-onset PD in Han Chinese. Additionally, mutation data should be interpreted carefully because even a synonymous mutation could cause abnormal mRNA splicing.

AB - Mutations of PLA2G6 gene have been lately proposed to be the causative gene for PARK14 in patients with autosomal recessive young-onset parkinsonism (YOPD). The role of PLA2G6 mutations as a risk factor for Parkinson's disease is not clear. To study the PLA2G6 mutations in PARK14-linked patients and its association with the onset of sporadic Parkinson's disease (sPD), sequencing and gene dosage analyses were carried out in 25 patients (onset age ≦30 years) then the identified variants were assessed in 956 sporadic PD (sPD) patients and 802 age-matched healthy controls. Four genetic variants were identified; one patient had homozygous c.991G>T (p.Asp331Tyr) mutation, two had compound heterozygous c.991G>T/c.1077G>A (p.Met358IlefsX) mutation, one had single c.1976A>G (p.Asn659Ser) mutation, and one patient had an exon 1 hetero-deletion. The c.1077G>A mutation resulted in a 4-bp deletion in leukocyte mRNA by activating a cryptic splice site in exon 7. Only p.Asp331Tyr was identified in four sPD patients and four controls. The onset age for PLA2G6 mutation carriers was younger than that for sPD (29.86±8.59 vs. 56.84±11.33 years, P=0.0002). The analysis of previously reported PARK14 patients revealed that those who carried a truncated mutation tended to have a complicated phenotype and atrophies of cortex and cerebellum. In conclusion, PLA2G6 mutation was the second common genetic cause after PRKN mutation in our YOPD patients and might be a risk factor for early-onset PD in Han Chinese. Additionally, mutation data should be interpreted carefully because even a synonymous mutation could cause abnormal mRNA splicing.

KW - Multiple-ligation probe amplification (MLPA)

KW - PARK14

KW - Parkinson's disease

KW - PLA2G6

KW - Splice site

UR - http://www.scopus.com/inward/record.url?scp=84862959258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862959258&partnerID=8YFLogxK

U2 - 10.1002/ajmg.b.32012

DO - 10.1002/ajmg.b.32012

M3 - Article

C2 - 22213678

AN - SCOPUS:84862959258

VL - 159 B

SP - 183

EP - 191

JO - American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

JF - American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

SN - 1552-4841

IS - 2

ER -